IN2014DN07752A - - Google Patents

Info

Publication number
IN2014DN07752A
IN2014DN07752A IN7752DEN2014A IN2014DN07752A IN 2014DN07752 A IN2014DN07752 A IN 2014DN07752A IN 7752DEN2014 A IN7752DEN2014 A IN 7752DEN2014A IN 2014DN07752 A IN2014DN07752 A IN 2014DN07752A
Authority
IN
India
Prior art keywords
microbiota
subject
altering
methods
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Lee M Kaplan
Alice P Liou
Peter J Turnbaugh
Jason L Harris
Original Assignee
Ethicon Endo Surgery Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49003107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethicon Endo Surgery Inc, Gen Hospital Corp filed Critical Ethicon Endo Surgery Inc
Publication of IN2014DN07752A publication Critical patent/IN2014DN07752A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
IN7752DEN2014 2012-02-29 2013-02-28 IN2014DN07752A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604824P 2012-02-29 2012-02-29
US13/780,284 US9173910B2 (en) 2012-02-29 2013-02-28 Compositions of microbiota and methods related thereto
PCT/US2013/028271 WO2013130773A2 (en) 2012-02-29 2013-02-28 Compositions of microbiota and methods related thereto

Publications (1)

Publication Number Publication Date
IN2014DN07752A true IN2014DN07752A (enExample) 2015-05-15

Family

ID=49003107

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7752DEN2014 IN2014DN07752A (enExample) 2012-02-29 2013-02-28

Country Status (6)

Country Link
US (11) US9173910B2 (enExample)
EP (1) EP2836224A4 (enExample)
CN (3) CN104780932A (enExample)
BR (1) BR112014021388A2 (enExample)
IN (1) IN2014DN07752A (enExample)
WO (1) WO2013130773A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4032586T3 (fi) 2010-02-01 2025-11-25 Ferring Microbiome Inc Bakteeriterapia clostridium difficile -koliittiin
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP2932424A2 (en) * 2012-12-13 2015-10-21 Metabogen AB Identification of a person having risk for developing type 2 diabetes
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9526480B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US9549703B2 (en) 2013-11-27 2017-01-24 Elwha Llc Devices and methods for sampling and profiling microbiota of skin
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9610037B2 (en) 2013-11-27 2017-04-04 Elwha Llc Systems and devices for profiling microbiota of skin
US9526450B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
WO2015164555A1 (en) 2014-04-23 2015-10-29 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
US10361003B2 (en) 2014-04-28 2019-07-23 Yeda Research And Development Co. Ltd. Method and apparatus for predicting response to food
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
WO2015178653A1 (ko) * 2014-05-20 2015-11-26 이화여자대학교 산학협력단 Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
EP3188741A4 (en) * 2014-08-28 2018-03-28 Yale University Compositions and methods for the treating an inflammatory disease or disorder
CA2962907C (en) * 2014-10-02 2022-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3047853B1 (en) * 2015-01-26 2019-05-15 Stephanie Lynch Broth compositions and their use as prebiotics
CN107980043B (zh) 2015-05-06 2021-09-24 瓦赫宁恩大学 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物
EP3915552A1 (en) 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
WO2016201053A1 (en) * 2015-06-09 2016-12-15 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
PT3626081T (pt) * 2015-09-10 2022-02-25 Univ Catholique Louvain Akkermansia pasteurizada para promover a perda de peso
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
US10960030B2 (en) 2016-04-15 2021-03-30 National Health Research Institutes Anti-obesity microbiota compositions and preparation methods and uses thereof
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
PT3468573T (pt) 2016-06-14 2023-10-16 Vedanta Biosciences Inc Tratamento de uma infeção por clostridium difficile
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US10441612B2 (en) * 2016-08-16 2019-10-15 Taichung Veterans General Hospital Intestinal microbe therapy, composition therefor and method for preparing the same
US11311573B2 (en) 2016-11-30 2022-04-26 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
CN107043714B (zh) * 2016-12-13 2021-03-12 广州康泽医疗科技有限公司 一种益生菌及其制备方法
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CA3076359A1 (en) * 2017-10-13 2019-04-18 Rebiotix, Inc. Microbiome health index
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
US20200345036A1 (en) * 2018-01-04 2020-11-05 White Dog Labs, Inc. Method and composition for improving health of an animal comprising cells of organism consisting of the strains within the order clostridiales
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
US12161680B2 (en) 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
EP3853605A4 (en) * 2018-09-18 2022-07-06 Mcpharma Biotech Inc. DETECTION, TREATMENT AND MONITORING OF MICROBIOME-INDUCED METABOLIC DYSFUNCTION
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
EP4010315A4 (en) * 2019-08-09 2023-11-15 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES
JP7417321B2 (ja) * 2019-09-25 2024-01-18 ヘルスバイオミー 癌治療のための絶対嫌気性人体腸内微生物及びその用途
CA3153884A1 (en) 2019-10-07 2021-04-15 Nikole KIMES Therapeutic pharmaceutical compositions
DK180598B1 (da) * 2020-02-21 2021-10-14 Sander Wilbek Theis Stivelsespropanoat anvendt som tilsætningsstof og/eller kosttilskud til mennesker til forebyggelse af overvægt og fedme
CN111388488A (zh) * 2020-04-10 2020-07-10 中国海洋大学 半乳寡糖及其衍生物在作为防治非酒精性脂肪肝药物中的应用
EP4181910A4 (en) * 2020-07-17 2024-06-05 DSM Nutritional Products, LLC OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE
BE1028339B1 (fr) 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
WO2022155443A1 (en) * 2021-01-15 2022-07-21 Yale University Compositions and methods for treating and preventing diseases or disorders using inter-species interactions
US20240268432A1 (en) 2021-07-23 2024-08-15 Universidade Católica Portuguesa - Ucp Encapsulated bacterial, methods and uses thereof
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1423823A (fr) 1964-11-20 1966-01-07 Azote Office Nat Ind Procédé de reformage catalytique et sous pression élevée des hydrocarbures pétroliers par la vapeur
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5143845A (en) 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
WO1994015635A1 (en) 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
CZ2001951A3 (cs) 1998-09-17 2001-11-14 Baxter Healthcare S. A. Prostředky obsahující streptokokový Cbeta protein
JP2003522731A (ja) 1998-12-11 2003-07-29 ウレックス バイオテック インク． 泌尿生殖器感染に対する処置および防止のための乳酸菌の経口投与方法
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
EP1206523B1 (en) 1999-08-05 2009-03-11 Société des Produits Nestlé S.A. Bifidobacteria preventing diarrhea caused by pathogenic bacteria
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
US7550285B2 (en) 2001-02-06 2009-06-23 Nestec S.A. Endotoxin binding lactic acid bacteria and bifidobacteria
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
CN1301708C (zh) 2002-02-21 2007-02-28 雀巢产品有限公司 用于皮肤光保护的人用口服组合物
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
CA2559596A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
MXPA06015184A (es) 2004-06-23 2007-11-22 Nestec Sa Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas.
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
JP2008518936A (ja) 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Ｒｓｖ感染症および関連状態を予防および治療する方法
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
JP4953824B2 (ja) 2004-12-28 2012-06-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 宿主に対して抗病性を付与する新規な菌株および菌体組成物
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20070042953A1 (en) 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
EP2040724B1 (en) * 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
CN1850047A (zh) * 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
KR20090127180A (ko) 2007-03-28 2009-12-09 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
BRPI0810087A2 (pt) 2007-03-28 2014-10-21 Alimentary Health Ltd Cepas de bifidobacterium probióticas
PL2142635T3 (pl) 2007-05-03 2019-01-31 Tobias Olofsson Nowe szczepy bakterii wyizolowane z przewodu wytwarzania miodu u pszczół miodnych
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
ES2578261T3 (es) 2007-05-18 2016-07-22 Nestec S.A. Lactobacillus johnsonii para prevenir infecciones postoperatorias
US20090010891A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
US20090010892A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
US7919250B2 (en) 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009043856A2 (en) 2007-10-01 2009-04-09 University College Cork, National University Of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
US20090143713A1 (en) 2007-11-30 2009-06-04 Jacques Van Dam Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
DK2318513T3 (da) 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
US9771624B2 (en) 2008-11-11 2017-09-26 The Procter & Gamble Company Bifidobacterium longum
KR101783383B1 (ko) 2009-05-07 2017-09-29 테이트 ＆ 라일 인그레디언츠 프랑스 에스에이에스 알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법
CA2761573A1 (en) 2009-05-11 2010-11-18 Nestec S.A. Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
WO2010146568A2 (en) 2009-06-19 2010-12-23 Danisco A/S Bifidobacteria for treating diabetes and related conditions
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
ES2708450T3 (es) 2009-07-30 2019-04-09 Dupont Nutrition Biosci Aps Bacterias ácido lácticas y bifidobacterias para tratar endotoxemia
EP2289527B1 (en) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
WO2011043654A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
PH12012500687A1 (en) 2009-11-12 2012-10-29 Nestec Sa Nutritional composition for promoting gut microbiota balance and health
US20130108585A1 (en) 2009-12-16 2013-05-02 Giovanni Mogna Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
WO2011099514A1 (ja) 2010-02-10 2011-08-18 日環科学株式会社 好熱性微生物を用いた混合物、溶解液、及び医薬品
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9439933B2 (en) 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
ES2744576T3 (es) 2010-06-30 2020-02-25 Nestle Sa Uso de ácido cicórico y bacteria láctica en suplemento alimenticio para aclarar y/o blanquear el tono de la piel
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
US20130224164A1 (en) 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
PL2944690T3 (pl) 2010-10-11 2018-05-30 Jennewein Biotechnologie Gmbh Nowe fukozylotransferazy i ich zastosowanie
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
CN103687604A (zh) 2011-03-01 2014-03-26 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
EP3610881A1 (en) * 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
US9463169B2 (en) 2011-08-17 2016-10-11 Microbiome Therapeutics, Llc Human gastrointestinal microbiome modulating food supplement for improving blood glucose regulation
DK2744888T3 (en) 2011-08-18 2018-03-12 Chr Hansen As Process for purifying bacterial cells
JP6116568B2 (ja) 2011-08-30 2017-04-19 アカデミッシュ メディッシュ セントラム インスリン抵抗性を予防および／または処置する方法
CA2848762C (en) 2011-09-14 2021-07-27 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
WO2013067185A1 (en) 2011-11-02 2013-05-10 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CN104010648A (zh) 2011-12-07 2014-08-27 可尔必思株式会社 包含乳酸菌或其处理物的脂质代谢和/或糖代谢改善剂
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
WO2014029783A1 (en) 2012-08-20 2014-02-27 Chr. Hansen A/S Method for freeze drying a bacteria-containing concentrate
KR20150118084A (ko) 2012-09-20 2015-10-21 프로테라 인코포레이티드 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법
US20150283144A1 (en) 2012-11-01 2015-10-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
EP4512479A3 (en) 2012-11-19 2025-05-21 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Also Published As

Publication number Publication date
CN108771687A (zh) 2018-11-09
EP2836224A4 (en) 2015-12-16
US20200121736A1 (en) 2020-04-23
US20170368108A1 (en) 2017-12-28
US12048721B2 (en) 2024-07-30
US20130224155A1 (en) 2013-08-29
CN104780932A (zh) 2015-07-15
US20200121733A1 (en) 2020-04-23
US20190046590A1 (en) 2019-02-14
US20200121732A1 (en) 2020-04-23
WO2013130773A3 (en) 2014-12-18
US10149867B2 (en) 2018-12-11
WO2013130773A8 (en) 2014-10-16
BR112014021388A2 (pt) 2017-07-18
WO2013130773A2 (en) 2013-09-06
US20200121734A1 (en) 2020-04-23
CN110201003A (zh) 2019-09-06
EP2836224A2 (en) 2015-02-18
US10729732B2 (en) 2020-08-04
US10149870B2 (en) 2018-12-11
US20200121735A1 (en) 2020-04-23
US20160113971A1 (en) 2016-04-28
US9173910B2 (en) 2015-11-03
US11590176B2 (en) 2023-02-28
US20200237835A1 (en) 2020-07-30
US20200246395A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
IN2014DN07752A (enExample)
HK1218560A1 (zh) 组成与方法
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EP2440210A4 (en) METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
PH12013500472A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
IN2015DN03219A (enExample)
MX340985B (es) Compuestos de n-heteroarilo.
MX2014013499A (es) Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos.
WO2014030049A3 (en) Compositions comprising a single variable domain and camostat mesylate (cm)
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
BR112016017765A8 (pt) composição compreendendo cinamaldeído e zinco, seu uso, e método para produzir um produto alimentício para perda de peso